The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivakine, E. A.
Right arrow Articles by Danska, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivakine, E. A.
Right arrow Articles by Danska, J. S.
The Journal of Immunology, 2005, 174: 7129-7140.
Copyright © 2005 by The American Association of Immunologists

Sex-Specific Effect of Insulin-Dependent Diabetes 4 on Regulation of Diabetes Pathogenesis in the Nonobese Diabetic Mouse1

Evgueni A. Ivakine*,{dagger},§, Casey J. Fox*,{dagger},§, Andrew D. Paterson{dagger}, Steven M. Mortin-Toth*,{dagger}, Angelo Canty*,{dagger},**, David S. Walton*,{dagger}, Katarina Aleksa{ddagger},¶, Shinya Ito{ddagger},¶ and Jayne S. Danska2,{dagger},§,||,#

Programs in* Developmental Biology,{dagger} Genetics and Genomic Biology, and{ddagger} Integrative Biology, Hospital for Sick Children, Toronto, Canada; Departments of§ Immunology, Pharmacology, and|| Medical Biophysics and# Institute of Medical Sciences, University of Toronto, Toronto, Canada; and** Department of Mathematics and Statistics, McMaster University, Hamilton, Canada


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Many human autoimmune diseases are more frequent in females than males, and their clinical severity is affected by sex hormone levels. A strong female bias is also observed in the NOD mouse model of type I diabetes (T1D). In both NOD mice and humans, T1D displays complex polygenic inheritance and T cell-mediated autoimmune pathogenesis. The identities of many of the insulin-dependent diabetes (Idd) loci, their influence on specific stages of autoimmune pathogenesis, and sex-specific effects of Idd loci in the NOD model are not well understood. To address these questions, we analyzed cyclophosphamide-accelerated T1D (CY-T1D) that causes disease with high and similar frequencies in male and female NOD mice, but not in diabetes-resistant animals, including the nonobese diabetes-resistant (NOR) strain. In this study we show by genetic linkage analysis of (NOD x NOR) x NOD backcross mice that progression to severe islet inflammation after CY treatment was controlled by the Idd4 and Idd9 loci. Congenic strains on both the NOD and NOR backgrounds confirmed the roles of Idd4 and Idd9 in CY-T1D susceptibility and revealed the contribution of a third locus, Idd5. Importantly, we show that the three loci acted at distinct stages of islet inflammation and disease progression. Among these three loci, Idd4 alleles alone displayed striking sex-specific behavior in CY-accelerated disease. Additional studies will be required to address the question of whether a sex-specific effect of Idd4, observed in this study, is also present in the spontaneous model of the disease with striking female bias.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Type 1 diabetes (T1D)3 is a complex disease of autoimmune etiology in which susceptibility is conferred by allelic variation at many loci. At least 20 insulin-dependent diabetes (Idd) loci have been identified in the diabetes-prone NOD mouse (1), and human genome scans have revealed similarly complex inheritance (2). In both species, the primary susceptibility locus, Idd1, is the MHC class II haplotype that controls Ag-specific T cell recognition (1). Evidence that the NOD Idd13.1 locus is a functional allele of {beta}2-microglobulin (3) accords with human studies in which variation in MHC class I also contributes to T1D susceptibility (4). A strong association was reported between polymorphisms in Ctla-4 and susceptibility to human T1D, Graves’ disease, and autoimmune hypothyroidism. Interestingly, the abundance of a ligand-independent Ctla-4 splice variant was shown to be 3–4 times lower in NOD compared with T1D-resistant C57BL10 mice (5), leading to differences in T cell responses between strains (6). The remaining Idd loci are not defined at the DNA sequence level. Because T1D is a clinical end point of the interaction of many genes in complex pathways, the influence of individual loci has been hard to resolve. We have examined the idea that preclinical phenotypes would display stronger inheritance with higher penetrance and involve contributions of fewer genes, enabling high resolution mapping and identification of T1D genes.

To focus on Idd loci predicted to exert strong effects on disease susceptibility, we compared the disease-prone NOD with the closely related, nonobese T1D-resistant (NOR) strain. NOR is a recombinant inbred strain that is 88% identical by descent with NOD including the Idd1 locus (H2g7), but is protected from both spontaneous and cyclophosphamide (CY)-accelerated T1D (CY-T1D) by genes of C57BLKS/J (BKs) origin (7). The BKs strain was derived from C57BL/6 and DBA/2 stocks (8). Analysis of 19 Idd loci in NOD and NOR by our group (9) and others (10, 11) demonstrated that NOD and NOR differ only at Idd 4, 5, 9, and Idd13 (Fig. 1). Previously, we reported that NOR mice display benign, early stage insulitis with minimal T cell contribution (12) and mapped this preclinical trait to the Idd5 and Idd13 loci. These two intervals exerted strong control over T cell recruitment to islet lesions, an obligate step in insulitis progression (9).



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 1. NOR is a recombinant inbred strain of 88% NOD and 12% BKs origin. Microsatellite markers with chromosomal locations according to <http://informatics.jax.org/ccr> and the positions of Idd1, 4, 5, 9, and 13 loci in agreement with a previous report (10 ) are indicated. The Idd4 was subsequently subdivided into two subloci, Idd4.1 and Idd4.2 (52 ), both of which could be located within the BKs-derived region on the NOR chromosome 11. To date, three subloci are found within Idd5. A gene for the Idd5.1 locus has been recently identified as Ctla-4 (5 ); this region is identical by descent in NOD and NOR. Both Idd5.2 (44 ) and Idd5.3 (9 ) are within the BKs-derived region on NOR chromosome 1. Three Idd9 subloci are mapped within the Idd9 (34 ). Only Idd9.1 and Idd9.2 are located within the BKs-derived interval on NOR chromosome 4. Idd13 is now subdivided into the Idd13.1 and Idd13.2 subloci (11 ), both of which are located within the BKs-derived region on NOR chromosome 2. NOD and NOR mice are identical by descent at the major diabetes susceptibility locus Idd1 on chromosome 17. NOR mice were shown to be homozygous for NOD alleles at Idd 15, 16, 17, 18, and 19 (data not shown).

 
CY accelerates T1D onset in both NOD male and female mice from months to only 3 wk (13). Similarly treated T1D-resistant strains (14), including NOR (7), remain disease free after CY treatment. First examined for prevention of T1D in NOD mice, this lymphotoxic drug paradoxically accelerated diabetes development in this strain, and both males and female mice were equally affected (13). Cases of T1D onset after CY treatment for lymphoma have also been reported in human patients with high risk MHC class II alleles (15). Although the mechanism of CY-accelerated T1D is not fully understood, the drug does not directly damage islet cells at the concentrations used in NOD mice (16), and the drug effect requires macrophages/dendritic cells and T cells similar to spontaneous disease (reviewed in Ref.17). The sex difference in spontaneous T1D frequency (~85% NOD female and 15–40% of NOD males) (18) has largely confined study of the disease to NOD females. We took advantage of the similarly high frequency of T1D in both sexes after CY treatment (Ref.13 and this study) to search for autosomal loci with possible sex-dependent effects. CY-accelerated insulitis progression was used as a trait in genetic analysis of a cohort of (NOD x NOR) F1 x NOD backcross mice revealing significant linkage to Idd4 and Idd9. A series of reciprocal congenic strains were derived and tested for susceptibility to CY-accelerated and spontaneous T1D. These data validated linkage to Idd4 and Idd9 and revealed the contribution of a third locus, Idd5. Comparative analyses of Idd4, Idd9, and Idd5 congenic strains indicated that these loci operate at distinct stages in progression to T1D. Importantly, our data revealed striking sex specificity in the behavior of Idd4 alleles in CY-accelerated model of the disease.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

All mice used in this study were maintained in a barrier facility at The Hospital for Sick Children. In our colony, the spontaneous diabetes incidence at age 6 mo in NOD/Jsd animals is 83% in females and 35% in males, and it is 0% in NOR and (NOD x NOR) F1 mice.

Genomic DNA preparation

For microsatellite genotype analysis, genomic DNA was prepared from tail snips (0.6–0.8 cm long) using a DNA easy kit (Qiagen). Each preparation was diluted 1/20 for use in PCR amplification.

Genotyping of backcross progeny

Genotyping of (NOD x NOR) x NOD backcross progeny was performed as previously described (9). Sixty-six backcross animals were typed for microsatellite alleles at Idd4 (D11Mit51, D11Mit87, D11Mit339, D11Mit30, and D11Mit219), Idd5 (D1Mit46), Idd11 (D4Mit146, D4Mit11, D4Mit338, D4Mit72, D4Mit251, and D4Mit13), and Idd13 (D2Mit17). These mice were also typed at C57BLKS/J-derived regions in the NOR genome that do not contain known Idd loci on chromosomes 5 (D5Mit11), 7 (D7Mit105), 12 (D12Mit230), and 18 (D18Mit4 and D18Mit21). The order of these markers was obtained from the Whitehead Institute for Biomedical Research/Massachusetts Institute of Technology Center for Genome Research). For most primer pairs, DNA was amplified for 35–40 cycles under the following conditions: 30 s at 94°C, 30 s at 55°C, and 1 min at 72°C in 1.5 mM MgCl2. For D11Mit30, D4Mit11, and D18Mit21, PCR was performed for 40 cycles (30 s at 94°C, 40 s at 50°C, and 1 min 10 s at 72°C in 2.5 mM MgCl2). The amplification products were electrophoresed through 2% NuSieve (American Bioanalytical) and 2% agarose (Invitrogen Life Technologies) gels and were visualized with ethidium bromide.

Generation of congenic and double congenic mice

NOD.NOR-Idd4, NOD.NOR-Idd5, NOD.NOR-Idd9, and NOD.NOR-Idd13 congenic mice were developed by intercrossing with NOR/Lt mice purchased from The Jackson Laboratory, followed by a backcross with NOD/Jsd mice with marker-assisted breeding. The following markers were used: D1Mit430, 3, 122, 212, 46, 44, and 305; D2Mit395, 338, 490, 412, and 452; D4Mit31, 33, 322, 219, 177, 157, 310, 217, 230, 151, 340, 146, 16, 251, and 259; D5Mit11; D7Mit105; D11Mit74, 340, 230, 135, 217, 310, 164, 157, 177, 4, 368, 30, 90, 364, 219, 322, and D11Bhm149; D12Mit76 and 230; and D18Mit4 and 21. For all markers, DNA was amplified with the following conditions: 10 cycles of 30 s at 94°C, 30 s at 50°C, and 1 min at 72°C, followed by 35 cycles of 30 s at 94°C, 30 s at 55°C, and 1 min at 72°C in 1.5 mM MgCl2. NOR.NOD-Idd4, NOR.NOD-Idd5, NOR.NOD-Idd9, and NOR.NOD-Idd13 mice were generated using a similar strategy. All animals used for this study were of the N5–6 F3–6 generations. Marker analysis was initiated at the first backcross and then continued for each generation. NOR.NOD-Idd4 and NOR.NOD-Idd9 mice were intercrossed to produce NOR.NOD-Idd4/Idd9 double-congenic mice. Similarly, NOR.NOD-Idd5/Idd13 double-congenic mice were generated from the intercross between NOR.NOD-Idd5 and NOR.NOD-Idd13 single-congenic animals.

CY treatment and insulitis assessment

Thirty-day-old mice were injected i.p. with 300 mg/kg freshly dissolved cyclophosphamide (Procytox), purchased from ASTA Medica). Pancreata were then removed from the mice 3, 7, or 14 days after injection; immediately immersed in TissueTec (Bayer Laboratories); snap-frozen in liquid nitrogen; and stored at –70°C. Preparation of frozen sections was performed with a CM 3050 Cryostat (Leica Canada). To maximize analysis of independent islet infiltrates, several 5-µm sections were prepared at least 300 µm apart. Pancreatic sections were stained with Mayer’s H&E Y (Sigma-Aldrich) to visualize leukocyte infiltration. Assessment of insulitis severity in pancreatic sections was performed as previously described (9). Briefly, ≥100 independent islets from three or more tissue depths were examined in each animal and graded according to the following criteria: 0, no visible infiltrates; 1, peri-insulitis, as indicated by perivascular and peri-islet infiltrates; 2, <25% of the islet interior occluded by leukocytes displaying invasive infiltrates (leukocytes evident in islet interior); 3, >25%, but <50%, of the islet interior occluded by leukocytes; or 4, complete infiltration, with the islet displaying invasive insulitis involving 50–100% of the islet field. For backcross analysis, animals were treated with a single dose of 300 mg/kg CY, as described above, pancreata from both male and female mice were removed 14 days after drug administration, and insulitis severity was determined using the same scoring scheme.

CY treatment and diabetes assessment of congenic mice

To induce diabetes, 10- to 12-wk-old mice of both genders were treated with two i.p. injections of freshly dissolved CY (Procytox), administered 14 days apart. The corresponding doses for the first and second injections were 300 and 200 mg/kg, respectively. Blood glucose levels were measured on days 14, 21, 24, 27, and 35 after the first injection using a FastTake blood glucose monitor (LifeScan Canada). Mice with blood glucose levels >16 mmol/L on two subsequent measurements were considered diabetic. Animals with high blood glucose on day 14 were monitored for an additional 3 days without a second CY injection. None of these mice reverted to normoglycemia; thus, all were included in the diabetic cohort. Pancreata were collected from normoglycemic mice on day 35 after the first injection, and insulitis severity was assessed as described above.

Assessment of spontaneous diabetes

Blood glucose levels were measured in NOD and NOD.NOR-Idd4 congenic females biweekly using a FastTake blood glucose monitor (LifeScan Canada). Animals were classified as diabetic when blood glucose levels were >16 mmol/L for two subsequent measurements. Diabetic mice also displayed polyuria, polydipsia, and weight loss.

Quantitation 4-hydroxycyclophosphamide (4-OH-CY) in plasma

4-OH-CY was measured in mouse plasma by liquid chromatography/mass spectrometry using a currently unpublished method (D. Stempak, K. Aleksa, S. Baruchel, G. Koren, and S. Ito, unpublished observations). Blood samples were drawn 20 min after injection. Once drawn, 200 µl of blood was immediately placed into tubes containing 20 µl of 2 M O-methylhydroxylamine hydrochloride (Sigma-Aldrich Canada). The O-methylhydroxylamine hydrochloride forms a stable derivative with the aldophosphamide. Samples were inverted several times, then centrifuged, and the plasma was transferred to clean tubes. The tubes were left at room temperature for 24 h. Aldophosphamide was extracted with diethyl ether. The aqueous layer was removed and discarded, and the organic layer was dried under nitrogen. Samples were reconstituted with 100 µl of acetonitrile/water (1/1) before liquid chromatography/mass spectrometry analysis. The low limit of quantitation for OXIME was 2.5 fmol on the column. A standard curve was generated using 4-hydroxlyperoxycyclophosphamide (provided by Dr. U. Niemeyer, ASTA Medica, Frankfurt, Germany).

Statistical analysis

Quantitative trait linkage analysis was performed as follows. A genetic map was built on the basis of the Whitehead Institute for Biomedical Research/Massachusetts Institute of Technology Center for Genome Research marker order, and markers were analyzed for trait linkage by the MAP-MAKER EXP (version 3.0) and QTL (version 1.1) suite of programs (19) (Genome Center software information and documentation). Multipoint analysis was conducted using recessive, dominant, and additive models. The logarithm of odds (LOD) scores, the proportion of the trait variance explained, and 1-LOD confidence intervals were determined with inclusion of all animals, and then separately by sex. Permutation analysis was performed for all animals using Map Manager QTXb20 (20, 21).

To examine strain or sex differences in the levels of 4-OH-CY, values from NOD and NOR mice, both males and females, were compared using one-way ANOVA. The difference in diabetes incidence between strains was assessed using Fisher’s exact test in SPSS for personal computer (version 8.01).

To test for sex-by-strain interaction effect in T1D incidence, we performed logistic regression analysis in which the log odds were modeled as a linear function of the covariates. This analysis is similar to factorial ANOVA, commonly used in Drosophila genetics to study sex-dependent effects of loci (22, 23, 24, 25, 26, 27, 28, 29, 30). In our case, sex and strain were two discrete covariates. We consider there to be a sex-dependent effect of a locus if the ratio of the odds of diabetes in the parental strain and the odds of diabetes in the congenic strain is different for the two genders. To test for this, we fit a logistic regression model with three terms: a main effect for sex, a main effect for strain, and a sex-by-strain interaction term. We also fit a second model without the interaction term. This model assumes that the log odds ratio is the same in both sexes. A test statistic for the significance of the sex-dependent effect is twice the difference in log likelihoods between these two models that has a {chi}2 distribution with a single degree of freedom if the null hypothesis of no interaction is true. The p values given in our results were obtained using this {chi}2 distribution.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Cyclophosphamide-induced severe insulitis depends on Idd1

We examined insulitis severity (IS) in age-matched NOD, NOR, (NOD x NOR) F1, as well as genetically unrelated BALB/c and C57BL/6 (B6) mice treated with CY. Insulitis was absent from CY-treated B6 and BALB/c animals and remained mild (IS <1.0) in treated NOR mice (Fig. 2a). This latter observation is consistent with the noninvasive insulitis previously reported in NOR animals (12). In contrast, IS in NOD mice rose dramatically after treatment (Fig. 2a), in agreement with a previous report (31), and all NOD animals maintained for 18 days post-treatment became diabetic (data not shown). Progression to severe insulitis and diabetes was not observed in CY-treated (NOD x NOR) F1 animals.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2. Effect of CY treatment on insulitis severity. a, CY induces severe insulitis in treated NOD, but not in other strains. a and b, Four-week-old NOD ({square}), B6 ({blacksquare}), BALB/c (•), NOR ({circ}), and (NOD x NOR) F1 ({triangleup}) female mice were given 300 mg/kg CY by i.p. injection and were sacrificed days 3, 7, and 14 after CY treatment. Controls were littermates that did not receive CY. b, MHC haplotype and lymphocyte dependence of CY-accelerated severe insulitis. {square}, NOD; {blacktriangleup}, MHC-congenic NOD.H2q; {blacktriangledown}, NOD.H2b; {circ}, lymphocyte-deficient NOD.SCID. The methods are described in a. Results in a and b are averaged from four to seven individual mice ± SD.

 
To address the contribution of the NOD-derived MHC (H2g7) haplotype to the CY-associated phenotypes, we examined their appearance in congenic mice that lacked the NOD (Idd1) haplotype and retained the remaining NOD-derived Idd loci. These animals are resistant to both spontaneous and CY-accelerated diabetes (32). After CY administration, both NOD.H2b and NOD.H2q mice displayed mild or undetectable insulitis (Fig. 2b). Thus, CY-induced insulitis progression, like spontaneous diabetes, required the NOD-derived Idd1 haplotype. However, NOR mice, which are also H2g7 homozygotes, did not display this CY phenotype (Fig. 2a), supporting the obligate contribution of loci that are not identical by descent in NOR and NOD animals. Finally, NOD.Prkcscid mice were absolutely resistant to CY-induced insulitis, indicating that mature lymphocytes are required in the process (Fig. 2b).

Biotransformation of CY in NOD and NOR mice

An immune etiology of CY-accelerated T1D is supported by previous studies (reviewed in Ref.17) and the genetic analysis described above. However, the biological basis for differential susceptibility in NOD and NOR mice was unclear, because they are MHC identical, and both displayed spontaneous, early stage insulitis at the time of drug treatment. One possibility is that their differential susceptibility to CY-induced insulitis progression and diabetes reflects differential biotransformation of the pro-drug into 4-OH-CY that decomposes into the alkylating compounds phosphoramide mustard and acrolein. To test this idea, cohorts of 70-day-old NOD and NOR animals of both sexes were injected with 300 mg/kg CY, and their plasma was analyzed using ion trap mass spectrometry and liquid chromatography. Time-course analysis showed that 4-OH-CY was maximal in both strains 20 min postinjection (data not shown). No significant differences between the strains or sexes in levels of 4-OH-CY were observed (p = 0.21, by one-way ANOVA (data not shown)). Therefore, differential susceptibilities to CY-induced insulitis progression and T1D in NOD and NOR mice resulted from distinct responses to the active drug.

Multipoint linkage analysis of CY-accelerated insulitis progression

To identify loci that might segregate with CY-accelerated insulitis and diabetes, we first defined the regions of the NOD and NOR genomes that are not identical by descent (Fig. 1). Idd 1–3, 6–8, 10, 12, and 14 were previously reported to be identical by descent in NOD and NOR mice (7). Microsatellite typing was performed for Idd 15–19 (33) and showed that NOR and NOD mice are genetically identical at these loci. Additional regions of allelic variation on chromosomes 5, 7, 10, 12, 14, and 18 are present, but have not been linked to diabetes risk (10) (Fig. 1). Thus, of 19 known diabetes susceptibility loci, NOR and NOD mice differed only at Idd 4, 5, 9, and 13. High resolution mapping by others has indicated that up to three disease-relevant loci are present at Idd9 (34). Additional fine mapping will be needed to resolve the relationship of Idd9 and Idd11, which reside on overlapping segments of chromosome 4 (34, 35, 36). In this study we use Idd9 to denote this region of chromosome 4.

Next, we examined 66 (NOD x NOR) F1 x NOD backcross progeny for linkage of progression to severe insulitis to markers designating Idd4, 5, 9, and 13 as well as other C57BLKS/J-derived regions of the NOR genome (Fig. 1). Twenty-four percent of the backcross progeny exhibited progression to severe insulitis (average IS, 3.69) consistent with the involvement of two unlinked loci. Multipoint linkage analysis of the phenotype:genotype distribution revealed significant linkage (37) to markers overlying Idd4 and Idd9 (Fig. 3; LOD score, 4.9 (30% variance explained); LOD score, 7.4 (43% variance explained)). No other markers tested displayed significant linkage to the trait. Analysis of 10,000 permutations confirmed significance of the linkage to both Idd4 and Idd9 (p < 0.0001; data not shown). We constructed a general linear model using PROC GLM (SAS Institute; version 9.1) with insulitis as the outcome and sex, and genotypes at D11Mit219 and D4Mit338 as independent variables. As expected, genotype at D11Mit219 and D4Mit338 were significantly associated with insulitis (p < 0.0001). There was no significant difference in the linkage between males and females at the peak markers for Idd4 and Idd9 (F = 1.6; 1 df; p > 0.2).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 3. Idd4 and Idd9 mediate CY-induced invasive insulitis. The LOD scores computed for linkage of CY-accelerated invasive insulitis are shown relative to the distance in centimorgans from the centromere of chromosome 4 (a) and chromosome 11 (b). The bar beneath each graph depicts microsatellite markers used in the critical intervals. Marker order was adapted from <http://genome.wi.mit.edu> and was confirmed using the Ensembl mouse assembly (<http://ensembl.org/>). Backcross progeny were not mapped for markers centromeric to D4Mit146 (a) or telomeric to D11Mit219 (b) because they are close to the boundary of the BKS-derived regions in NOR mice. Pairwise comparisons, using MAPMAKER QTL analysis, were performed (37 ).

 
Strikingly, progression to severe insulitis was only observed in backcross progeny homozygous for NOD alleles at both Idd4 and Idd9 loci. Animals homozygous at both Idd4 and Idd9 (n = 15) had significantly greater insulitis severity than animals with other genotypes at these two loci (Fig. 4). These interactions were significant (by ANOVA, p < 0.0005) and suggested a role for NOD-derived gene products at both Idd4 and Idd9 in CY-accelerated insulitis progression.



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 4. Insulitis severity in CY-treated backcross mice. Backcross progeny were parsed into all combinations of Idd4 (D11Mit219) and Idd9 (D4Mit11) genotypes (x-axis): homozygous (NN) for NOD-derived alleles at both loci, heterozygous (NB) at Idd4 and homozygous for NOD alleles at Idd9, heterozygous at Idd9 and homozygous at Idd4, and heterozygous at both loci. Only animals homozygous for NOD alleles at both Idd and Idd9 loci displayed progression to severe insulitis. {diamondsuit}, Males; {diamond}, females.

 
The linkage analysis provided evidence for 1 LOD confidence intervals at a 7.8-cM interval (37–44.8 cM from the centromere) for Idd4, and a 12.4-cM interval (53.6–66.0 cM from the centromere) for Idd9 (Fig. 3). Both locations were consistent with previous reports in which Idd4 was localized to an interval between 27–72 cM from the centromere on chromosome 11 (38), Idd9 to a 24-cM interval 58–82 cM (36), and Idd11 to a 12-cM region 59–71 cM from the centromere on chromosome 4 (39). The probable locations of both Idd4 and Idd9 were confirmed, and Idd4 was further refined by the linkage results presented in this study.

Analysis of Idd4 and Idd9 congenic strains

We next determined whether the impact of Idd4 and Idd9 on the CY-accelerated disease process could be observed when the regions were separated from other genes. Using marker-assisted breeding, we generated reciprocal congenic strains on the NOD and NOR backgrounds and examined their responses to CY (Fig. 5 and Table I). Idd4 congenic mice were made on the NOD and NOR backgrounds: NOR.NOD-Idd4 (33.8-cM interval), NOD.NOR-Idd4 long (27.8-cM interval), and NOD.NOR-Idd4 short (6.9-cM interval). A 26.7-cM interval including Idd9 was introgressed to produce NOR.NOD-Idd9 and NOD.NOR-Idd9 mice (Fig. 5). Finally, a double-congenic strain on the NOR background, NOR.NOD-Idd4/Idd9, was made to examine the combined affects of these two NOD-derived regions on the CY response (Fig. 5a).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 5. Congenic (a and b) and double-congenic (c) strains generated on the NOD (a), and NOR (b and c) genetic backgrounds. Marker-directed breeding was used to derive the congenic strains presented in this study (see Materials and Methods). The subloci, Idd4.1, Idd4.2, Idd5.2, Idd5.3, Idd9.1, Idd9.2, Idd13.1, and Idd13.2 (Fig. 1), that are different between NOD and NOR were captured in the corresponding reciprocal congenics. During production of these lines, markers on all chromosomes that were not identical by descent between NOD and NOR were typed. These were found to be of parental background in the congenic lines, with the exception of the introgressed interval(s) displayed (data not shown).

 

View this table:
[in this window]
[in a new window]
  		Table I. Phenotype of Idd4, Idd5, Idd9, and Idd13 congenic strains after CY administrationa

 
As expected, NOD males and females progressed to T1D, and NOR mice of both sexes were relatively resistant (Table I). NOD.NOR-Idd4 (long) and NOD.NOR-Idd9 congenic females showed significant protection from disease (p = 0.005 and p = 0.002, respectively), as did NOD.NOR-Idd9 males (p = 0.002). In striking contrast, NOD.NOR-Idd4 males were not protected relative to NOD males (p = 0.96). These results demonstrate that NOR-derived alleles at both loci confer resistance to CY-accelerated T1D, with the effects of NOR alleles at Idd4 restricted to females. To further refine location of the Idd4 locus, we evaluated CY-T1D in females of the NOD.NOR-Idd4 short strain. They were significantly protected from the disease compared with NOD mice (p = 0.003), placing Idd4 within the 6.9-cM interval and defining the centromeric boundary of the locus at D11Mit30. Importantly, both long and short NOD.NOR-Idd4 strains were also protected from spontaneous T1D (Fig. 6), suggesting that common immunogenetic mechanisms involved in Idd4-mediated protection in both forms of the disease.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 6. Cumulative frequency of spontaneous T1D in NOD and NOD.NOR-Idd4 congenic females defining boundaries of the Idd4 interval. Diabetes development was monitored as described in Materials and Methods.

 
To determine whether NOD-derived Idd4 or Idd9 conferred T1D susceptibility on the NOR background, we analyzed NOR.NOD-Idd4, NOR.NOD-Idd9, and NOR.NOD-Idd4/Idd9 double-congenic mice (Table I). The NOD-derived loci enhanced T1D incidence compared with NOR mice. A strong effect was observed in NOR.NOD-Idd4 males (p = 0.0001), and a moderate effect was shown in females (p = 0.016). NOR.NOD-Idd9 females displayed significantly enhanced susceptibility (p = 0.002), with males of this strain also showing increased susceptibility (p = 0.03). NOR.NOD-Idd4/Idd9 double-congenic females and males were significantly more susceptible to CY-T1D compared with sex-matched NOR controls (p = 0.0002 and p = 0.001, respectively). However, in both sexes of NOR.NOD-Idd4/Idd9 mice, T1D incidence was lower than in NOD animals, probably reflecting the effects of additional NOR resistance alleles in this background. Linkage analysis was performed on (NOD x NOR) F1 x NOD backcross animals (Fig. 3), in which the contributions of NOR resistance loci with a recessive mode of inheritance were not detected. Because NOR mice carry Idd5 and Idd13 loci previously implicated in spontaneous T1D, these regions were considered likely candidates to contain the gene(s) responsible for the observed protection.

Analysis of Idd5 and Idd13 congenic strains

To evaluate possible contributions of Idd5 and/or Idd13 loci in response to CY, we generated NOD.NOR-Idd5 (18.2-cM interval), NOD.NOR-Idd13 (23.0-cM interval), NOR.NOD-Idd5 (18.2-cM interval), and NOR.NOD-Idd13 (13.2-cM interval) congenic and NOR.NOD-Idd5/Idd13 double-congenic mice using a marker-assisted speed congenic approach (Fig. 5). Both males and females of the NOD.NOR-Idd5 strain were protected from CY-T1D (p = 0.0005 and p = 0.0004, respectively), whereas NOD.NOR-Idd13 mice developed the disease as frequently as their NOD counterparts (Table I). To determine whether NOD-derived Idd5 and Idd13, either alone or in combination, could confer susceptibility to T1D, NOR.NOD-Idd5, NOR.NOD-Idd13, and NOR.NOD-Idd5/Idd13 mice were treated with CY. None of these strains showed enhanced CY-T1D susceptibility compared with NOR mice (Table I). Thus, despite strong disease protection conferred by the NOR-derived Idd5, the NOD-derived Idd5, alone or even in combination with the NOD-derived Idd13, was not sufficient to confer susceptibility to CY-T1D. Importantly, these data distinguish the effects of NOD alleles at Idd5 and Idd13 from those at Idd4 and Idd9 that did confer susceptibility to NOR mice with CY-accelerated disease.

Alleles at the Idd4 locus display sex-specific effect

Genotype-by-sex interaction can occur if a phenotypic trait affects only one sex (sex-specific effects), affects both sexes but to different degrees (sex-biased effects), or affects both sexes in opposite directions (sex-antagonistic effects) (reviewed in Ref.22). Having noticed a striking effect of sex on susceptibility to CY-T1D in NOD.NOR-Idd4 congenic mice vs the parental NOD strain (p = 0.96 and p = 0.005 for males and females, respectively; Table I), we further investigated this matter using logistic regression analysis (Fig. 7). We used approaches developed in Drosophila complex trait genetics, where multiple sex-specific QTL have been described (22, 23, 24, 25, 26, 27, 28, 29, 30), to look for a sex-specific effect of the Idd loci in the current study. A sex-by-strain interaction effect of T1D incidence was only statistically significant when NOD and NOD.NOR-Idd4 mice were compared (p = 0.0194), supporting the idea of sex-specific behavior of alleles at the Idd4 locus. The sex-by-strain interaction effect was not observed in the NOR vs NOR.NOD-Idd4 comparison (p = 0.203), indicating that the sex-specific effect of Idd4 is influenced by genetic background. Alleles at neither Idd5 nor Idd9 displayed sex-specific behavior in any of the comparisons performed (Fig. 7), suggesting that of the three loci influencing susceptibility to CY-T1D, only alleles at the Idd4 locus behave in a sex-specific manner.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 7. Sex-by-strain interaction plots for NOD (a) and NOR (b) congenic mice. The cumulative frequency of T1D (percentage) was plotted for both sexes in parental vs congenic strains. The sex-by-strain interaction effect was tested as described in Materials and Methods, using logistic regression analysis. Only the NOD vs NOD.NOR-Idd4 comparison resulted in a statistically significant interaction effect, providing evidence for sex-specific behavior of the Idd4 locus.

 
Possible mechanisms of CY-T1D protection in Idd4, Idd5, and Idd9 congenic strains

Having observed the impact of protective effects of NOR alleles at Idd4, Idd5, and Idd9 loci on CY-T1D incidence, we next examined the degree of islet inflammation in NOD and NOD congenic animals that remained normoglycemic 35 days after CY treatment. Ten of 62 (16%) CY-treated NOD mice did not become diabetic over the observation period. Histological analysis performed on pancreata from five of these 10 animals all displayed invasive insulitis (Fig. 8). Among NOD.NOR-Idd4 females, 14 of 35 (40%) remained normoglycemic at the conclusion of the experiment. As observed with NOD parental mice, seven of seven pancreata examined from these congenic mice displayed invasive insulitis (IS scores, 1.52–3.19). In contrast, nine of 25 randomly selected NOD.NOR-Idd9 mice that were normoglycemic after the observation period had only progressed to early peri-insulitis (IS scores, <1.0). Similarly, 13 of 15 NOD.NOR-Idd5 animals that were diabetes free at the end of the observation period had IS scores <1.0, indicating no progression to invasive insulitis. Ten of these mice displayed no insulitis (Fig. 8). These results suggested that NOR alleles at the Idd5 locus control early steps of insulitis progression in CY-treated animals, consistent with our previous evidence for control of early insulitits progression in spontaneous diabetes (9). The frequency of peri-insulitis in NOD.NOR-Idd9 differed from that in NOD mice (by Fisher’s exact test, p = 0.04), suggesting that NOR-derived alleles at this locus may limit progression from peri- to invasive insulitis. In contrast to Idd5 and Idd9, which conferred an effect on insulitis progression, IS scores in nondiabetic, CY-treated, NOD.NOR-Idd4 mice were similar to those in NOD controls, suggesting that NOR Idd4 alleles may protect (females) from a step following invasive insulitis during progression to {beta}-cell destruction.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 8. Insulitis severity in CY-treated nondiabetic mice. a, NOD animals and mice of CY-T1D-resistant congenic strains were treated with CY twice as described in Materials and Methods. Pancreases from mice that did not become diabetic 35 days after first injection were collected, and insulitis severity was assessed (b). Mice with insulitis severity >1 were considered to progress to invasive insulitis. NOD.NOR-Idd4, NOD.NOR-Idd5, and NOD.NOR-Idd9 congenic strains displayed different levels of islet invasiveness, suggesting that these loci control separate steps of diabetes pathogenesis.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We found that Idd4, Idd5, and Idd9 loci control susceptibility to CY-T1D, demonstrating that the drug-accelerated model is regulated by loci previously shown to impact spontaneous T1D risk in NOD mice. Idd1 H2g7 was necessary, but insufficient, to confer CY-accelerated insulitis. MHC-identical NOR mice were resistant to the CY effect, indicating the role of other non-MHC-linked NOD Idd alleles. Because no difference in biotransformation of CY into the active compounds was observed between NOD and NOR strains, the disease-promoting effect of the drug can now be ascribed to differential cellular responses to the active compound. Analysis of (NOD x NOR) x NOD backcross animals produced significant evidence of linkage of insulitis to markers consistent with Idd9 and Idd4. Importantly, only animals homozygous for NOD alleles at both loci displayed severe insulitis, suggesting interactions between these loci. Allelic variation at Idd4 or Idd9 displayed significant effects on CY-T1D in congenic mice constructed on both the NOD and NOR backgrounds. Thus, two Idd regions identified by linkage to an early step in disease progression displayed strong effects on disease outcome, validating the use of preclinical phenotypes for analysis of T1D. In addition, we observed strong protection from CY-T1D conferred by NOR alleles in NOD.NOR-Idd5 congenic strain. Allelic variation at Idd13 did not impact this disease model. NOR alleles at Idd4 provided strong protection from CY-T1D for females, but not males. Strong sex-by-strain interaction effect was observed by comparison of NOD and NOD.NOR-Idd4 strains, clearly demonstrating a sex-specific effect of the Idd4 locus on CY-T1D development. The distinction between sexually dimorphic traits and sex-specific locus effects in complex traits has emerged from analysis in model systems and now includes type 1 diabetes in the NOD mouse. Future studies will be required to determine whether allelic variation at Idd4 has an effect on the sexual dimorphism of spontaneous T1D.

Idd5

Idd5 was originally identified as a 34-cM interval on chromosome 1 that affected susceptibility to both spontaneous and cyclophosphamide-induced diabetes (40) as well as to peri-insulitis (41, 42). Analysis of recently developed Idd5 congenic strains in which portions of the C57BL/10 (B10) genome were introgressed into the NOD background suggested presence of two loci, Idd5.1 and Idd5.2, each conferring protection from insulitis and T1D ((43, 44); Fig. 9). Subsequent study further refined location of Idd5.1 to a small interval containing Ctla-4 (45), and recent work identified a Ctla-4 sequence variant affecting expression of a single splicing isoform between NOD and B10 mice (5). This study suggested that allelic variation at Ctla-4 mediates the T1D protection provided by B10-derived Idd5.1 locus. A high resolution map of chromosome 1 in NOR mice indicates that Ctla-4 is NOD derived in this strain (9) and therefore can be excluded as a candidate gene conferring protection from CY-T1D in the current study.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 9. Chromosomes 1, 4, and 11 in NOR mice. Intervals containing Idd5, Idd9, and Idd4 loci are shown. The thick bar with asterisk immediately to the left of chromosomes 4 and 11 represents 1 LOD confidence intervals from multipoint linkage analysis for CY-accelerated insulitis in (NOD x NOR) x NOD backcross mice. Narrow bars represent the locations of the Idd intervals defined by other groups in comparable studies. The original location of the Idd5 locus spans a region 20–60 cM from the centromere of chromosome 1 (41 73 ). Idd5 was subsequently subdivided into three subloci. The gene for the Idd5.1 locus was recently identified as Ctla-4 (5 ). This locus is identical by descent between NOD and NOR. Idd5.2 is located within a 1.52-cM interval between D1Mit180 and D1Mit46 (44 ). The location of the Idd5.3 locus is presented as 1-LOD confidence interval of the invasive insulitis phenotype in the (NOD x NOR) F2 intercross (9 ). Idd9 and Idd11 loci have been originally mapped to chromosome 4 (36 39 ). The refined location of the Idd11 interval is shown according to Brodnicki et al. (35 ) and spans a region from D4Mit119 to D4Mit204. Idd9 was subsequently subdivided into three subloci: Idd9.1, Idd9.2, and Idd9.3. Fine mapping of the telomeric boundary of the BK-derived region of NOR chromosome 4 indicated that Idd9.3 (mapped to the 2.0-cM region between D4Mit127 and D4Mit42 (34 )) is identical by descent between NOD and NOR (Ref.9 and this study). Idd9.1 was mapped to the 35.7-cM interval between microsatellite markers D4Mit27 and D4Mit251, and Idd9.2 was placed at the 5.6-cM region between D4Mit251 and D4Mit226 (34 ). Idd4 was originally mapped to the ~30 cM region on mouse chromosome 11 (38 40 ). The locus was subsequently subdivided into two subloci, Idd4.1 and Idd4.2, both of which were located in the 9.2-cM region between D11Mit30 and D11Mit41 (52 ). It should be noted that for mapping, most authors used NOD congenic strains with introgressed genomic regions from either B6 or B10 mice. NOR mice have genetic contributions from NOD, B6, and DBA/2 genomes. BKs-derived regions on NOR chromosome 1 are shown to be of B6 origin. On NOR chromosomes 4 and 11, regions from D4Mit31 to D4Mit338 and from D11Mit112 to D11Bhm149, respectively, are of DBA/2 origin. Regions from D4Mit72 to D4Mit160 and from D11mit340 to D11Mit164 are of B6 origin (Ref.9 and 10 and this study).

 
In an earlier study from our laboratory, a more telomeric portion of chromosome 1, defined as Idd5.3, was identified in an (NOD x NOR) F2 intercross study as a locus that, together with Idd13, controlled islet invasiveness, specifically the transition from peri- to invasive insulitis (9). Idd5.3 is separated from Idd5.2 by ~12 cM. Both Idd5.2 and Idd5.3 intervals are BKs derived in the NOR strain, so genes within either or both of these loci may contribute to the protection from CY-T1D reported in this study. One attractive candidate is the natural resistance-associated macrophage protein (Nramp1) involved in the clearance of intracellular pathogens (46). This gene lies within the Idd5.2 region and is shown to be polymorphic between NOD and B10 strains (44). There are a number of genes without an obvious link to diabetes pathogenesis that map to the Idd5.3, including those for the nicotinic acetylcholine receptor, Acrg (47); collagen type VI, Col6a3 (48); the high density lipoprotein-binding protein, Hdlbp (49); and the receptor activity-modifying protein 1, Ramp1 (50).

Idd9

A large interval on the distal end of chromosome 4 was originally identified in the development of spontaneous diabetes in NOD mice (36, 38) (Fig. 9). In contrast to the current study, the previous reports did not observe linkage of CY-T1D to this region. However, in contrast to the data presented in this study, the cohort under study was 180 days old and free of spontaneous diabetes when treated with CY, and mice had been generated from NOD crosses to different T1D-resistant strains (C57BL/6.Thy1a and C57BL/10H2g7) (36). Later work from the same group resolved the 30-cM Idd9 region into three subregions (Idd9.1, 9.2, and 9.3) by analysis of congenic strains (34). Although Idd9.1 was not tested on its own, the NOD.B10-Idd9 congenic line containing B10 alleles at all three subregions was significantly more resistant to spontaneous T1D than shorter congenics lacking B10Idd9.1. The Idd9.1 overlaps our 1 LOD confidence interval, and both the Idd9.1 and Idd9.2 regions lie within the Idd9 congenic intervals reported in this study (Figs. 5 and 9). Because the Idd9.3 region is identical by descent in NOD and NOR mice, it probably does not contribute to the diabetes phenotypes described in this study. Interestingly, Lyons et al. (34) also showed that despite diabetes resistance, NOD.B10-Idd9 mice displayed severe islet inflammation. Thus, for spontaneous disease, Idd9 appears to control a late step that affects {beta}-cell death rather than the magnitude of islet inflammation.

Morahan et al. (39) reported a fourth generation ((C57BL/6 x NOD) F1 x NOD) backcross analysis and concluded that heterozygosity at Idd11 (their designation) conferred protection from CY-accelerated disease despite homozygosity for NOD alleles at Idd1, 2, 3, 4, and 5. These data agree with our evidence that NOD alleles at Idd1, 4, and 9 drive susceptibility to CY-accelerated disease. The same group reported mapping B6-derived resistance to spontaneous T1D in congenic animals and suggested that the critical Idd11 interval lay between D4Mit31 (50.3 cM) and D4Mit204 (61.2 cM) (35) (Fig. 9). This location aligns with the 1-LOD confidence interval and was included in the Idd9 congenic strains reported in this study. Thus, previous studies and the data presented in this study identify potent Idd susceptibility genes between D4Mit331 and D4Nds13 that affect spontaneous T1D- and CY-accelerated insulitis and T1D.

Idd4 and genetic similarities between T cell-mediated autoimmune diseases

Idd4 was first identified in a genome-wide linkage analysis of (NOD x B10.H2g7) x NOD animals as a 30-cM region on chromosome 11 linked to early-onset T1D (38) (Fig. 9). Later studies examined linkage of this region to thymocyte proliferative unresponsiveness in NOD mice, a phenotype measured by in vitro ligation of the T cell Ag receptor with multivalent Ab (51). NOD thymocytes displayed lower proliferation than C57BL/6 and equal proliferation with DBA/2 thymocytes. The relationship of this phenotype to T1D susceptibility is not known. The same group later reported linkage of Idd4 with T1D pathogenesis in NOD.B6 congenic animals, suggesting that the maximal diabetes resistance was located within a 9.2-cM interval between D11Mit30 and D11Mit41 (52) (Fig. 9). Of several interesting candidate genes in this region, a favorite includes one that encodes inducible NO synthase (Nos2), an enzyme that produces NO, associated with {beta}-cell destruction (53). The Scya cluster of monocyte-specific chemokine and chemokine receptor genes also maps in this region (54) and may help direct lymphocyte and monocyte recruitment to the islets. Interestingly, a locus (eae7) controlling susceptibility to experimental allergic encephalitis (EAE), a mouse model of autoimmune demyelinating disease with similarities to human multiple sclerosis (MS), also maps in the middle of the Idd4 region (55). Subsequent comparison of coding sequences of members of the Scya gene cluster between EAE-resistant and susceptible strains detected polymorphisms resulting in nonconservative amino acid substitutions in Scya 1, 2, and 12 (56). Thus, allelic variation in the Idd4 region may affect susceptibility to multiple T cell-mediated autoimmune disorders. Higher resolution genetic analysis and direct tests of variants in transgenic models will be required to determine whether this reflects a true sharing of autoimmunity genes among different diseases. Immunological studies support similarities in the autoimmune responses in these diseases. For example, T cells in MS and T1D patients were found to target an overlapping set of autoantigens expressed in islet cells and the CNS. When treated with a protocol similar to that used to induce EAE, NOD mice displayed rapid, progressive CNS inflammation and demyelination (57). Thus, both genetic and functional evidence support shared mechanisms of T cell-mediated autoimmunity that ultimately targets different tissues.

Sexual dimorphism in autoimmune disease

Sexual dimorphism in NOD T1D incidence was apparent from the first report of this strain (58) and could be manipulated by surgical castration of either sex (59). Previous genetic studies of spontaneous insulitis and diabetes only examined females and so were unable to detect sex-dependent effects of Idd alleles. The use of CY in the current study allowed evaluation of both sexes, demonstrating that allelic variation at the Idd4 had distinct effects on male and female congenic mice (Table I). The sex specificity at this locus was dramatic, where NOR alleles protected females (p = 0.005), but had no significant effect on males (p = 0.96), and logistic regression analysis identified strong sex-by-strain interaction effect when NOD and NOD.NOR-Idd4 mice were compared (p = 0.0194). Taken together with the previous reports and our finding (Fig. 6) that Idd4 impacts spontaneous T1D susceptibility, these observations provide a genetic basis for the sexual dimorphism in NOD T1D susceptibility and predict that the action of the critical genes at Idd4 will be sex dependent.

The existence of sex-influenced loci was recently established in several animal models of autoimmunity, such as EAE (60) and proteoglycan-induced arthritis (61) in mice and collagen-induced arthritis in rats (62). Interestingly, in both EAE and proteoglycan-induced arthritis models, linkage analysis to disease susceptibility identified several loci displaying differential behaviors in males vs females, with one of them mapping to the interval overlapping our Idd4. In the collagen-induced arthritis model, fine mapping of arthritis severity in congenic rat strains revealed two loci, Cia3 and Cia5, located on chromosomes 4 and 10, respectively, with different effects in males and females (62). Cia5 was previously mapped to the telomeric portion of chromosome 10 (63) in an interval that is syntenic to the segment of mouse chromosome 11 where we positioned Idd4. Taken together with our work, these studies suggest a sex-dependent locus that either coincides with or is located in the close proximity to Idd4, affecting susceptibility to multiple autoimmune diseases involving distinct MHC haplotypes and tissue-specific reactions. Interestingly, a common functional variant in the protein tyrosine phosphatase (PTPN22) have been recently identified in T1D, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients (64, 65, 66). Future studies will be directed at genetic and genomic analyses of potentially shared susceptibility genes, and allelic variants for autoimmune diseases in rodent models and patient populations.

Many autoimmune diseases, including Sjogren’s syndrome, RA, SLE, MS, and autoimmune thyroiditis, occur at substantially higher frequencies in females than in males. The issue is more complex with T1D and is related to the substantial worldwide variation in incidence ranging from <1 to 36/100,000. Geographic regions with higher T1D incidence generally do not show a sex bias. However, in Japanese, Oceanic, and African-American populations with lower disease incidence, a higher T1D incidence has been observed in females (67, 68, 69). In addition to sex effects on incidence, the presentation and severity of many autoimmune diseases differ between men and women. The strongest evidence that sex steroid hormones modulate the human immune response come from studies during pregnancy, when estrogen and progesterone levels rise and peak during the third trimester. Symptoms and signs of MS and RA frequently decline during pregnancy, but can flare in the postpartum period when levels of these hormones fall (70, 71). Conversely, pregnancy does not improve and often augments autoimmune activity in SLE (72). One explanation for these observations is that pregnancy induces a Th2-dominated immune response, enhancing Ab-mediated tissue damage in SLE and suppressing Th1 cell-mediated immune responses that drive MS and RA. However, there is little direct evidence for this idea, and the mechanisms of sexual dimorphism in autoimmune disease are probably more complex, involving neuroendocrine factors and epigenetic modification of gene expression.

Evidence from human populations and rodent models demonstrates that generation of an islet-reactive T cell repertoire depends upon MHC haplotype, and that destruction of islet {beta}-cells requires coinheritance of multiple diabetes susceptibility loci. Diabetes susceptibility may be conferred by different constellations of genes in mice and humans as well as in genetically diverse human populations. The NOD model provides opportunities to analyze both the mechanisms of disease pathogenesis and their genetic control, thus elucidating shared immunological pathways within which lie potential targets for therapeutic intervention.


   Acknowledgments
 
We thank Allison Jeffery for islet histology, and Drs. C. Guidos, L. McAllister, S. Scherer, and R. McInnes for helpful discussions and critical comments on the manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a grant from the Canadian Institutes for Health Research (MOP-64216) and Genome Canada. E.A.I and C.J.F. were supported by the Hospital for Sick Children Research Training Center and the Banting and Best Diabetes Center Novo-Nordisk Studentship. K.A. was supported by Canadian Institutes for Health Research studentship. A.D.P. is the Canada Research Chair in Genetics of Complex Diseases and holds Premier’s Research Excellence Award. J.S.D. is a Principal Investigator of the Canadian Genetic Disease Network. Back

2 Address correspondence and reprint requests to Dr. Jayne S. Danska, Program in Developmental Biology, Hospital for Sick Children Research Institute, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. E-mail address: Jayne.Danska{at}sickkids.ca Back

3 Abbreviations used in this paper: T1D, type 1 diabetes; CY, cyclophosphamide; EAE, experimental allergic encephalitis; Idd, insulin-dependent diabetes; IS, insulitis severity; LOD, logarithm of odds; MS, multiple sclerosis; NOR, nonobese diabetes resistant; 4-OH-CY, 4-hydroxycyclophosphamide; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus. Back

Received for publication September 13, 2004. Accepted for publication March 14, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Wicker, L. S., J. A. Todd, L. B. Peterson. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13: 179-200.[Medline]
  2. Cox, N. J., B. Wapelhorst, V. A. Morrison, L. Johnson, L. Pinchuk, R. S. Spielman, J. A. Todd, P. Concannon. 2001. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am. J. Hum. Genet. 69: 820-830.[Medline]
  3. Hamilton-Williams, E. E., D. V. Serreze, B. Charlton, E. A. Johnson, M. P. Marron, A. Mullbacher, R. M. Slattery. 2001. Transgenic rescue implicates {beta}2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc. Natl. Acad. Sci. USA 98: 11533-11538.[Abstract/Free Full Text]
  4. Noble, J. A., A. M. Valdes, T. L. Bugawan, R. J. Apple, G. Thomson, H. A. Erlich. 2002. The HLA class I A locus affects susceptibility to type 1 diabetes. Hum. Immunol. 63: 657-664.[Medline]
  5. Ueda, H., J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. Hunter, A. N. Smith, G. Di Genova, et al 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.[Medline]
  6. Vijayakrishnan, L., J. M. Slavik, Z. Illes, R. J. Greenwald, D. Rainbow, B. Greve, L. B. Peterson, D. A. Hafler, G. J. Freeman, A. H. Sharpe, et al 2004. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20: 563-575.[Medline]
  7. Prochazka, M., D. V. Serreze, W. N. Frankel, E. H. Leiter. 1992. NOR/Lt mice: MHC-matched diabetes-resistant control strain for NOD mice. Diabetes 41: 98-106.[Abstract]
  8. Naggert, J. K., J. L. Mu, W. Frankel, D. W. Bailey, B. Paigen. 1995. Genomic analysis of the C57BL/Ks mouse strain. Mamm. Genome 6: 131-133.[Medline]
  9. Fox, C. J., A. D. Paterson, S. M. Mortin-Toth, J. S. Danska. 2000. Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis. Am. J. Hum. Genet. 67: 67-81.[Medline]
  10. Serreze, D. V., M. Prochazka, P. C. Reifsnyder, M. M. Bridgett, E. H. Leiter. 1994. Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin-dependent diabetes resistance gene. J. Exp. Med. 180: 1553-1558.[Abstract/Free Full Text]
  11. Serreze, D. V., M. Bridgett, H. D. Chapman, E. Chen, S. D. Richard, E. H. Leiter. 1998. Subcongenic analysis of the Idd13 locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for {beta}2-microglobulin. J. Immunol. 160: 1472-1478.[Abstract/Free Full Text]
  12. Fox, C. J., J. S. Danska. 1998. Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 47: 331-338.[Abstract]
  13. Harada, M., S. Makino. 1984. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27: 604-606.[Medline]
  14. Charlton, B., T. E. Mandel. 1989. Recurrence of insulitis in the NOD mouse after early prolonged anti-CD4 monoclonal antibody treatment. Autoimmunity 4: 1-7.[Medline]
  15. Atlan-Gepner, C., R. Bouabdallah, R. Valero, D. Coso, B. Vialettes. 1998. A cyclophosphamide-induced autoimmune diabetes. Lancet 352: 373-374.[Medline]
  16. Charlton, B., A. Bacelj, R. M. Slattery, T. E. Mandel. 1989. Cyclophosphamide-induced diabetes in NOD/WEHI mice: evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 38: 441-447.[Abstract]
  17. Yoon, J. W., H. S. Jun, P. Santamaria. 1998. Cellular and molecular mechanisms for the initiation and progression of {beta} cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27: 109-122.[Medline]
  18. Pozzilli, P., A. Signore, A. J. Williams, P. E. Beales. 1993. NOD mouse colonies around the world: recent facts and figures. Immunol. Today 14: 193-196.[Medline]
  19. Lander, E. S., P. Green, J. Abrahamson, A. Barlow, M. J. Daly, S. E. Lincoln, L. Newburg. 1987. MAPMAKER: an interactive computer package for constructing primary genetic linkage maps of experimental and natural populations. Genomics 1: 174-181.[Medline]
  20. Churchill, G. A., R. W. Doerge. 1994. Empirical threshold values for quantitative trait mapping. Genetics 138: 963-971.[Abstract]
  21. Manly, K. F., R. H. Cudmore, Jr, J. M. Meer. 2001. Map Manager QTX, cross-platform software for genetic mapping. Mamm. Genome 12: 930-932.[Medline]
  22. Anholt, R. R., T. F. Mackay. 2004. Quantitative genetic analyses of complex behaviours in Drosophila. Nat. Rev. Genet. 5: 838-849.[Medline]
  23. Mackay, T. F.. 2001. Quantitative trait loci in Drosophila. Nat. Rev. Genet. 2: 11-20.[Medline]
  24. Long, A. D., S. L. Mullaney, L. A. Reid, J. D. Fry, C. H. Langley, T. F. Mackay. 1995. High resolution mapping of genetic factors affecting abdominal bristle number in Drosophila melanogaster. Genetics 139: 1273-1291.[Abstract]
  25. Gurganus, M. C., J. D. Fry, S. V. Nuzhdin, E. G. Pasyukova, R. F. Lyman, T. F. Mackay. 1998. Genotype-environment interaction at quantitative trait loci affecting sensory bristle number in Drosophila melanogaster. Genetics 149: 1883-1898.[Abstract/Free Full Text]
  26. Nuzhdin, S. V., E. G. Pasyukova, C. L. Dilda, Z. B. Zeng, T. F. Mackay. 1997. Sex-specific quantitative trait loci affecting longevity in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 94: 9734-9739.[Abstract/Free Full Text]
  27. Nuzhdin, S. V., C. L. Dilda, T. F. Mackay. 1999. The genetic architecture of selection response: inferences from fine-scale mapping of bristle number quantitative trait loci in Drosophila melanogaster. Genetics 153: 1317-1331.[Abstract/Free Full Text]
  28. Weber, K., R. Eisman, L. Morey, A. Patty, J. Sparks, M. Tausek, Z. B. Zeng. 1999. An analysis of polygenes affecting wing shape on chromosome 3 in Drosophila melanogaster. Genetics 153: 773-786.[Abstract/Free Full Text]
  29. Vieira, C., E. G. Pasyukova, Z. B. Zeng, J. B. Hackett, R. F. Lyman, T. F. Mackay. 2000. Genotype-environment interaction for quantitative trait loci affecting life span in Drosophila melanogaster. Genetics 154: 213-217.[Abstract/Free Full Text]
  30. Wayne, M. L., J. B. Hackett, C. L. Dilda, S. V. Nuzhdin, E. G. Pasyukova, T. F. Mackay. 2001. Quantitative trait locus mapping of fitness-related traits in Drosophila melanogaster. Genet Res. 77: 107-116.[Medline]
  31. Zhang, Z. L., H. M. Georgiou, T. E. Mandel. 1993. The effect of cyclophosphamide treatment on lymphocyte subsets in the nonobese diabetic mouse: a comparison of various lymphoid organs. Autoimmunity 15: 1-10.[Medline]
  32. Wicker, L. S., M. C. Appel, F. Dotta, A. Pressey, B. J. Miller, N. H. DeLarato, P. A. Fischer, R. C. Boltz, Jr, L. B. Peterson. 1992. Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. J. Exp. Med. 176: 67-77.[Abstract/Free Full Text]
  33. Ikegami, H., S. Makino, E. Yamato, Y. Kawaguchi, H. Ueda, T. Sakamoto, K. Takekawa, T. Ogihara. 1995. Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J. Clin. Invest. 96: 1936-1942.
  34. Lyons, P. A., W. W. Hancock, P. Denny, C. J. Lord, N. J. Hill, N. Armitage, T. Siegmund, J. A. Todd, M. S. Phillips, J. F. Hess, et al 2000. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity 13: 107-115.[Medline]
  35. Brodnicki, T. C., P. McClive, S. Couper, G. Morahan. 2000. Localization of Idd11 using NOD congenic mouse strains: elimination of Slc9a1 as a candidate gene. Immunogenetics 51: 37-41.[Medline]
  36. Rodrigues, N. R., R. J. Cornall, P. Chandler, E. Simpson, L. S. Wicker, L. B. Peterson, J. A. Todd. 1994. Mapping of an insulin-dependent diabetes locus, Idd9, in NOD mice to chromosome 4. Mamm. Genome 5: 167-170.[Medline]
  37. Lander, E., L. Kruglyak. 1995. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Genet. 11: 241-247.[Medline]
  38. Ghosh, S., S. M. Palmer, N. R. Rodrigues, H. J. Cordell, C. M. Hearne, R. J. Cornall, J. B. Prins, P. McShane, G. M. Lathrop, L. B. Peterson, et al 1993. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat. Genet. 4: 404-409.[Medline]
  39. Morahan, G., P. McClive, D. Huang, P. Little, A. Baxter. 1994. Genetic and physiological association of diabetes susceptibility with raised Na+/H+ exchange activity. Proc. Natl. Acad. Sci. USA 91: 5898-5902.[Abstract/Free Full Text]
  40. Todd, J. A., T. J. Aitman, R. J. Cornall, S. Ghosh, J. R. Hall, C. M. Hearne, A. M. Knight, J. M. Love, M. A. McAleer, J. B. Prins, et al 1991. Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature 351: 542-547.[Medline]
  41. Garchon, H. J., P. Bedossa, L. Eloy, J. F. Bach. 1991. Identification and mapping to chromosome 1 of a susceptibility locus for periinsulitis in non-obese diabetic mice. Nature 353: 260-262.[Medline]
  42. Garchon, H. J., J. J. Luan, L. Eloy, P. Bedossa, J. F. Bach. 1994. Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction. Eur. J. Immunol. 24: 380-384.[Medline]
  43. Hill, N. J., P. A. Lyons, N. Armitage, J. A. Todd, L. S. Wicker, L. B. Peterson. 2000. NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes 49: 1744-1747.[Abstract]
  44. Wicker, L. S., G. Chamberlain, K. Hunter, D. Rainbow, S. Howlett, P. Tiffen, J. Clark, A. Gonzalez-Munoz, A. M. Cumiskey, R. L. Rosa, et al 2004. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J. Immunol. 173: 164-173.[Abstract/Free Full Text]
  45. Lamhamedi-Cherradi, S. E., O. Boulard, C. Gonzalez, N. Kassis, D. Damotte, L. Eloy, G. Fluteau, M. Levi-Strauss, H. J. Garchon. 2001. Further mapping of the Idd5.1 locus for autoimmune diabetes in NOD mice. Diabetes 50: 2874-2878.[Abstract/Free Full Text]
  46. Govoni, G., P. Gros. 1998. Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm. Res. 47: 277-284.[Medline]
  47. Heidmann, O., A. Buonanno, B. Geoffroy, B. Robert, J. L. Guenet, J. P. Merlie, J. P. Changeux. 1986. Chromosomal localization of muscle nicotinic acetylcholine receptor genes in the mouse. Science 234: 866-868.[Abstract/Free Full Text]
  48. Schurr, E., E. Skamene, K. Morgan, M. L. Chu, P. Gros. 1990. Mapping of Col3a1 and Col6a3 to proximal murine chromosome 1 identifies conserved linkage of structural protein genes between murine chromosome 1 and human chromosome 2q. Genomics 8: 477-486.[Medline]
  49. Xia, Y. R., I. Klisak, R. S. Sparkes, J. Oram, A. J. Lusis. 1993. Localization of the gene for high-density lipoprotein binding protein (HDLBP) to human chromosome 2q37. Genomics 16: 524-525.[Medline]
  50. Derst, C., H. Engel, K. Grzeschik, J. Daut. 2000. Genomic structure and chromosome mapping of human and mouse RAMP genes. Cytogenet. Cell. Genet. 90: 115-118.[Medline]
  51. Gill, B. M., A. Jaramillo, L. Ma, K. B. Laupland, T. L. Delovitch. 1995. Genetic linkage of thymic T-cell proliferative unresponsiveness to mouse chromosome 11 in NOD mice: a possible role for chemokine genes. Diabetes 44: 614-619.[Abstract]
  52. Grattan, M., Q. S. Mi, C. Meagher, T. L. Delovitch. 2002. Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. Diabetes 51: 215-223.[Abstract/Free Full Text]
  53. Eizirik, D. L., M. Flodstrom, A. E. Karlsen, N. Welsh. 1996. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic {beta} cells. Diabetologia 39: 875-890.[Medline]
  54. Montgomery, J. C., K. A. Silverman, A. M. Buchberg. 1997. Chromosome 11. Mamm. Genome 7: S190-S208.
  55. Butterfield, R. J., J. D. Sudweeks, E. P. Blankenhorn, R. Korngold, J. C. Marini, J. A. Todd, R. J. Roper, C. Teuscher. 1998. New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice. J. Immunol. 161: 1860-1867.[Abstract/Free Full Text]
  56. Teuscher, C., R. J. Butterfield, R. Z. Ma, J. F. Zachary, R. W. Doerge, E. P. Blankenhorn. 1999. Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J. Immunol. 163: 2262-2266.[Abstract/Free Full Text]
  57. Winer, S., I. Astsaturov, R. Cheung, L. Gunaratnam, V. Kubiak, M. A. Cortez, M. Moscarello, P. W. O’Connor, C. McKerlie, D. J. Becker, et al 2001. Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. J. Immunol. 166: 2831-2841.[Abstract/Free Full Text]
  58. Makino, S., K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri, Y. Tochino. 1980. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 29: 1-13.[Medline]
  59. Makino, S., K. Kunimoto, Y. Muraoka, K. Katagiri. 1981. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu 30: 137-140.[Medline]
  60. Fillmore, P. D., M. Brace, S. A. Troutman, E. P. Blankenhorn, S. Diehl, M. Rincon, C. Teuscher. 2003. Genetic analysis of the influence of neuroantigen-complete Freund’s adjuvant emulsion structures on the sexual dimorphism and susceptibility to experimental allergic encephalomyelitis. Am. J. Pathol. 163: 1623-1632.[Abstract/Free Full Text]
  61. Adarichev, V. A., A. B. Nesterovitch, T. Bardos, D. Biesczat, R. Chandrasekaran, C. Vermes, K. Mikecz, A. Finnegan, T. T. Glant. 2003. Sex effect on clinical and immunologic quantitative trait loci in a murine model of rheumatoid arthritis. Arthritis Rheum. 48: 1708-1720.[Medline]
  62. Remmers, E. F., B. Joe, M. M. Griffiths, D. E. Dobbins, S. V. Dracheva, A. Hashiramoto, T. Furuya, J. L. Salstrom, J. Wang, P. S. Gulko, et al 2002. Modulation of multiple experimental arthritis models by collagen-induced arthritis quantitative trait loci isolated in congenic rat lines: different effects of non-major histocompatibility complex quantitative trait loci in males and females. Arthritis Rheum. 46: 2225-2234.[Medline]
  63. Griffiths, M. M., E. F. Remmers. 2001. Genetic analysis of collagen-induced arthritis in rats: a polygenic model for rheumatoid arthritis predicts a common framework of cross-species inflammatory/autoimmune disease loci. Immunol. Rev. 184: 172-183.[Medline]
  64. Bottini, N., L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, M. Rostamkhani, J. MacMurray, G. F. Meloni, P. Lucarelli, M. Pellecchia, et al 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36: 337-338.[Medline]
  65. Begovich, A. B., V. E. Carlton, L. A. Honigberg, S. J. Schrodi, A. P. Chokkalingam, H. C. Alexander, K. G. Ardlie, Q. Huang, A. M. Smith, J. M. Spoerke, et al 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75: 330-337.[Medline]
  66. Kyogoku, C., C. D. Langefeld, W. A. Ortmann, A. Lee, S. Selby, V. E. Carlton, M. Chang, P. Ramos, E. C. Baechler, F. M. Batliwalla, et al 2004. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75: 504-507.[Medline]
  67. Karvonen, M., M. Pitkaniemi, J. Pitkaniemi, K. Kohtamaki, N. Tajima, J. Tuomilehto. 1997. Sex difference in the incidence of insulin-dependent diabetes mellitus: an analysis of the recent epidemiological data: World Health Organization DIAMOND Project Group. Diabetes Metab. Rev. 13: 275-291.[Medline]
  68. Kida, K., G. Mimura, T. Ito, K. Murakami, I. Ashkenazi, Z. Laron. 2000. Incidence of type 1 diabetes mellitus in children aged 0–14 in Japan, 1986–1990, including an analysis for seasonality of onset and month of birth: JDS study: the Data Committee for Childhood Diabetes of the Japan Diabetes Society (JDS). Diabet. Med. 17: 59-63.[Medline]
  69. Matsuura, N., K. Fukuda, A. Okuno, S. Harada, N. Fukushima, A. Koike, Y. Ito, T. Hotsubo. 1998. Descriptive epidemiology of IDDM in Hokkaido, Japan: the Childhood IDDM Hokkaido Registry. Diabetes Care. 21: 1632-1636.[Abstract]
  70. Confavreux, C., M. Hutchinson, M. M. Hours, P. Cortinovis-Tourniaire, T. Moreau. 1998. Rate of pregnancy-related relapse in multiple sclerosis: Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339: 285-291.[Abstract/Free Full Text]
  71. Nelson, J. L., M. Ostensen. 1997. Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 23: 195-212.[Medline]
  72. Petri, M.. 1994. Systemic lupus erythematosus and pregnancy. Rheum. Dis. Clin. North Am. 20: 87-118.[Medline]
  73. Cornall, R. J., J. B. Prins, J. A. Todd, A. Pressey, N. H. DeLarato, L. S. Wicker, L. B. Peterson. 1991. Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/Ity/Bcg genes on chromosome 1. Nature 353: 262-265.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. H. Esensten, M. R. Lee, L. H. Glimcher, and J. A. Bluestone
T-bet-Deficient NOD Mice Are Protected from Diabetes Due to Defects in Both T Cell and Innate Immune System Function
J. Immunol., July 1, 2009; 183(1): 75 - 82.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. McDuffie, N. A. Maybee, S. R. Keller, B. K. Stevens, J. C. Garmey, M. A. Morris, E. Kropf, C. Rival, K. Ma, J. D. Carter, et al.
Nonobese Diabetic (NOD) Mice Congenic for a Targeted Deletion of 12/15-Lipoxygenase Are Protected From Autoimmune Diabetes
Diabetes, January 1, 2008; 57(1): 199 - 208.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. A. Ivakine, S. M. Mortin-Toth, O. M. Gulban, A. Valova, A. Canty, C. Scott, and J. S. Danska
The Idd4 Locus Displays Sex-Specific Epistatic Effects on Type 1 Diabetes Susceptibility in Nonobese Diabetic Mice
Diabetes, December 1, 2006; 55(12): 3611 - 3619.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
X. Li, H. Chen, and P. N. Epstein
Metallothionein and Catalase Sensitize to Diabetes in Nonobese Diabetic Mice: Reactive Oxygen Species May Have a Protective Role in Pancreatic {beta}-Cells
Diabetes, June 1, 2006; 55(6): 1592 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. A. Ivakine, O. M. Gulban, S. M. Mortin-Toth, E. Wankiewicz, C. Scott, D. Spurrell, A. Canty, and J. S. Danska
Molecular genetic analysis of the idd4 locus implicates the IFN response in type 1 diabetes susceptibility in nonobese diabetic mice.
J. Immunol., March 1, 2006; 176(5): 2976 - 2990.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivakine, E. A.
Right arrow Articles by Danska, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivakine, E. A.
Right arrow Articles by Danska, J. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS